Skip to content

Investors / Investor FAQs


The information contained in this FAQ section of Amarin's website is accurate only as of the date this page was last updated. Amarin disavows any obligation to update the information contained in this FAQ section after such date. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.


 

Please click here

Please click here

To see the complaint please click here 

To see the public interest statement please click here

To see the jurisdiction brief please click here

For opinion click here
For settlement click here

Amarin is pleased to announce the publication of “Rationale and Design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial” in the March issue of Clinical Cardiology.

The article can be accessed here. Also, an Amarin press release has been issued related to this publication.

The following are key points regarding the study design for REDUCE-IT:

REDUCE-IT: Study Design

  • REDUCE-IT is a landmark global study involving approximately 8,000 patients
  • It is a randomized, multicenter, double-blind, placebo-controlled study designed to determine if treatment with VASCEPA® 4 g/day versus placebo reduces major adverse cardiovascular events (MACE) in statin-treated patients with persistent hypertriglyceridemia and high cardiovascular risk
  • The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina
  • Secondary endpoints include time to event analyses of components of the primary endpoint
  • The study is being conducted under a special protocol assessment agreement with the FDA

For more information, please click here

In September 2014, the National Lipid Association (NLA) launched a nationwide triglyceride campaign during National Cholesterol Education Month. The NLA's announced goal is to encourage patient education and drive discussions about lipid management and the consequences of high cholesterol and triglyceride levels.

According to the NLA, the mission of the campaign is to encourage physicians to inform patients about the importance of proper treatment and prevention as it relates to their entire lipid profile - not just cholesterol, but elevated triglyceride levels, too.

"We want to raise awareness around elevated triglycerides with patients and health care providers alike, as they may unsuspectingly affect patients' health, even if they look and feel healthy," said NLA President Terry A. Jacobson, MD. "Fortunately, health care providers are committed to offering their patients their best care, and we're committed to ensuring they have the tools to do so."

In a recent survey of health care providers, the NLA discovered a need for standard protocols surrounding the measure of patients' total lipid profiles, including triglycerides. To jumpstart these educational and preventive efforts, the NLA urges health care providers to compare patients' triglyceride levels to the following categories:

With this campaign, NLA hopes to provide the necessary resources for clinical practice and education, as well as generate awareness about lipid management.

Amarin is not responsible for the content of NLA's campaign.

Amarin has a co-promotion agreement with Kowa through the end of 2018 under which Kowa uses a portion of the time of their sales force to help educate physicians in the U.S. on the use of Vascepa, along with promotion of its flagship branded statin product, LIVALO® (pitavastatin).  This co-promotion arrangement increases both the number of sales targets reached and the frequency of sales calls on existing sales targets. Kowa is responsible for the cost of its sales representatives and related promotional materials.  Amarin compensates Kowa with a co-promotion fee based on a percentage of Vascepa gross margins which fee is classified by Amarin as part of selling, general and administrative expenses.

Amarin's ordinary shares, represented by American Depositary Shares, are listed on the NASDAQ Capital Market under the ticker AMRN.

Until July 16th 2008, Amarin's ordinary shares were also listed on London's AIM (ticker: AMRN) and Dublin's IEX (ticker: H2E).

An American Depositary Share (ADS) is a security that represents an ownership interest in the shares of a foreign company trading on a U.S. securities market. The shares represented by the ADSs are held by a U.S. depositary bank and are evidenced by certificates called American Depositary Receipts (ADRs), although the terms ADS and ADR are often used interchangeably. ADRs enable U.S. investors to buy shares in foreign companies without undertaking cross-border transactions (i.e., in U.S. dollars), and they trade, clear and settle in accordance with U.S. market regulations and conventions.

Non-U.S. companies whose securities trade on a U.S. securities market.

One Amarin ADR equals one Amarin ordinary share.

Holders of ADRs may authorize Citibank, Amarin's Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADRs.

Amarin's fiscal year is the 12-month calendar year ending December 31st.

Please visit our website at www.amarincorp.com where you can read more on our executive team, board of directors, company strategy, corporate governance, therapeutic focus, product pipeline and partnering activities.

Amarin is headquartered in Dublin, Ireland.

Amarin's financial statements, including annual reports, can be found on Amarin's website www.amarincorp.com in the Investor Relations section here. Alternatively, you can find all of Amarin's filings with the U.S. Securities and Exchange Commission under the SEC Filings section of the website here.

The U.S. Transfer Agent for Amarin's ADS holders is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
USA
Tel: +1-877-248-4237

The Registrar for Amarin's ordinary shares is:

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013

AND

Equiniti
PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex,
BN99 6QQ, England
Telephone: +44 121 415 7047

The Depositary for Amarin's ADRs is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237
Fax: +1-201-324-3284
citibank@shareholders-online.com

Ernst & Young LLP
99 Wood Avenue South
Iselin, NJ 08830

You can register to receive updates announced by Amarin by submitting your email address on the Mailing List section of our website, which option can be found on each page of the website www.amarincorp.com. Alternatively you can send an email to investor.relations@amarincorp.com requesting to be notified of any new updates announced

Please contact: Elisabeth Schwartz
Tel: +1-908-719-1315
e-mail: investor.relations@amarincorp.com

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1957520013&CompanyID=AMRN&t=.jpg

Updated: September 27, 2017 at 12:13 PM Eastern Time